Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P04637: Variant p.Asp7His

Cellular tumor antigen p53
Gene: TP53
Feedback?
Variant information Variant position: help 7 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help US The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Aspartate (D) to Histidine (H) at position 7 (D7H, p.Asp7His). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and acidic (D) to medium size and polar (H) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In a sporadic cancer; somatic mutation. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 7 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 393 The length of the canonical sequence.
Location on the sequence: help MEEPQS D PSVEPPLSQETFSDLWKLLP The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         MEEPQSDPSVEPPLSQETFSDLWKLLP

                              MEESQSELNIDPPLSQETFSELWNLLP

Rhesus macaque                MEEPQSDPSIEPPLSQETFSDLWKLLP

Mouse                         MEESQSDISLELPLSQETFSGLWKLLP

Rat                           MEDSQSDMSIELPLSQETFSCLWKLLP

Pig                           MEESQSELGVEPPLSQETFSDLWKLLP

Bovine                        MEESQAELNVEPPLSQETFSDLWNLLP

Rabbit                        MEESQSDLSLEPPLSQETFSDLWKLLP

Sheep                         MEESQAELGVEPPLSQETFSDLWNLLP

Cat                           MQEPPLELTIEPPLSQETFSELWNLLP

Chicken                       -MAEEMEPLLEP---TEVFMDLWSMLP

Xenopus laevis                -MEPSSETGMDPPLSQETFEDLWSLLP

Zebrafish                     MAQNDSQE----------FAELWE---

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 393 Cellular tumor antigen p53
Region 1 – 320 Interaction with CCAR2
Region 1 – 83 Interaction with HRMT1L2
Region 1 – 44 Transcription activation (acidic)
Modified residue 9 – 9 Phosphoserine; by HIPK4
Modified residue 15 – 15 Phosphoserine; by CDK5, PRPK, AMPK, NUAK1 and ATM
Modified residue 18 – 18 Phosphothreonine; by CK1, VRK1 and VRK2
Modified residue 20 – 20 Phosphoserine; by CHEK2, CK1 and PLK3
Cross 24 – 24 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)
Alternative sequence 1 – 132 Missing. In isoform 7, isoform 8 and isoform 9.
Alternative sequence 1 – 39 Missing. In isoform 4, isoform 5 and isoform 6.
Mutagenesis 15 – 15 S -> A. Loss of interaction with PPP2R5C, PPP2CA AND PPP2R1A.
Mutagenesis 18 – 18 T -> A. No effect on interaction with MDM2 and increase in protein levels after DNA damage.
Mutagenesis 20 – 20 S -> A. Abolishes phosphorylation site. Abolishes increase in protein levels after DNA damage.
Mutagenesis 20 – 20 S -> D. Constitutively increased TP53 protein levels.
Mutagenesis 24 – 24 K -> R. Abolishes ubiquitination by MUL1.



Literature citations
No reference for the current variant in UniProtKB/Swiss-Prot.
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.